The progress of peptide vaccine clinical trials in gynecologic oncology

Hum Vaccin Immunother. 2022 Nov 30;18(5):2062982. doi: 10.1080/21645515.2022.2062982. Epub 2022 Jun 10.

Abstract

Peptide vaccine are a type of immunotherapy that are synthesized according to the amino acid sequence of known or predicted tumor antigen epitopes. They are safe and well tolerated and have shown exciting results in gynecologic oncology. However, no peptide vaccine has yet been licensed in this field. This review examines peptide vaccine clinical trials in gynecology registered on ClinicalTrials.gov through January 1, 2022, analyzes the global progress and current achievements of peptide vaccines in gynecology, and explores the efforts focused on devising new methods to boost immunotherapeutic outcomes, including the use of adjuvants, multi-epitope vaccines, combinations of helper T cell epitopes, personalized peptide vaccines, synthetic long peptides, new peptide delivery, and combination therapy.

Keywords: Peptide; adjuvant; cancer; gynecology; multi-Epitope; neoantigen.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cancer Vaccines*
  • Epitopes, T-Lymphocyte
  • Female
  • Genital Neoplasms, Female* / therapy
  • Humans
  • Peptides
  • Vaccines, Subunit / therapeutic use

Substances

  • Cancer Vaccines
  • Epitopes, T-Lymphocyte
  • Peptides
  • Vaccines, Subunit

Grants and funding

This work was supported by the Foundation of Key Research and Development Program of Science & Technology Department of Sichuan Province under Grant [2022YFS0227], the Foundation of Project of Chengdu Women and Children's Central Hospital under Grant [2022JC01], the Foundation of Chengdu High-level Key Clinical Specialty Construction Project.